Related Experiment Video

Updated: Jul 9, 2026

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

3D-QSAR CoMFA analysis of C5 substituted pyrrolotriazines as HER2 (ErbB2) inhibitors

Mahendra Awale1, C Gopi Mohan

  • 1Centre for Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, 160 062 Punjab, India.

Journal of Molecular Graphics & Modelling
|December 7, 2007
PubMed

Insights

New pyrrolotriazines show promise as dual inhibitors of HER2 and EGFR, key targets in human cancers. Structure-activity relationship analysis using 3D-QSAR CoMFA confirms their potential for cancer therapy development.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Computational Chemistry

Background:

  • Human cancers often exhibit increased activity of receptor tyrosine kinases (RTKs), including EGFR and HER2.
  • EGFR and HER2 are clinically validated targets for anti-cancer drug development.

Purpose of the Study:

  • To investigate pyrrolotriazine compounds as dual inhibitors of HER2 and EGFR.
  • To establish a quantitative structure-activity relationship (QSAR) for HER2 inhibition.

Main Methods:

  • Synthesis and evaluation of C4 and C5 substituted pyrrolotriazines.
  • 3D-QSAR Comparative Molecular Field Analysis (CoMFA) modeling.

Main Results:

  • Pyrrolotriazine derivatives demonstrated dual inhibition of HER2 and EGFR protein tyrosine kinases.
  • The developed CoMFA model exhibited statistically significant results and good predictive power for HER2 inhibition.

Conclusions:

  • Structural features of pyrrolotriazines are linked to their HER2 inhibitory activity.
  • These findings support the potential of pyrrolotriazines as targeted cancer therapeutics.

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...